Mercuric chloride: Toxicity and apoptosis in a human oligodendroglial cell line MO3.13

Biomaterials

Volumn 24, Issue 6, 2003, Pages 981-987

  Issa, Y ^a   Watts, D C ^a   Duxbury, A John ^a,b   Brunton, P A ^a   Watson, M B ^a   Waters, C M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY DENTAL HOSPITAL OF MANCHESTER   (United Kingdom)

Author keywords

Amalgam; Apoptosis; Mercury toxicity; Multiple sclerosis; Oligodendrocyte

Indexed keywords

ASSAYS; CELLS; CHROMATE COATINGS; MORPHOLOGY; PROTEINS; SHRINKAGE; TOXICITY;

OLIGODENDROGLIAL CELL LINE;

MERCURY COMPOUNDS;

AMALGAM; CASPASE; FODRIN; LAMIN B; MERCURIC CHLORIDE; MITOCHONDRIAL ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXIDOREDUCTASE; PROTEIN; PROTEINASE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL SWELLING; CELL VIABILITY; CHEMICAL ANALYSIS; CHROMATIN CONDENSATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEATH; ENVIRONMENTAL EXPOSURE; ENZYME ASSAY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MORPHOLOGY; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; POPULATION; PRIORITY JOURNAL; PROTEIN FAMILY; TOXICITY;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MERCURIC CHLORIDE; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; OLIGODENDROGLIA;

EID: 0037334199     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(02)00436-2     Document Type: Article

References (37)

1. Kaga M., Seale N.S., Hanawa T., Ferracane J.L., Okabe T. Cytotoxicity of amalgams. J Dent Res. 67(9):1988;1221-1224.
2. Galic N., Goranka P., Prester L., Blanusa M., Krnic Z., Ferercic Z. Dental amalgam mercury exposure in rats. Biomaterials. 12:1999;227-231.
3. Clarkson T.W. The toxicology of mercury. Crit Rev Clin Lab Sci. 34:1997;369-403.
4. Shenker B.J., Guo T.L., Shapiro I.M. Mercury-induced apoptosis in human lymphoid cells. evidence that the apoptotic pathway is mercurial species dependent Environ Res. 84(2):2000;89-99.
5. Langauer-Lewowica H., Zajac-Nedza M. Changes in the nervous system due to occupational metallic mercury poisoning. Neurol Neurochir Pol. 3(5):1997;905-913.
6. McGrother C.W., Dugmore C., Philips M.J., Raymond N.T., Garrick P., Baird W.O. Multiple sclerosis, dental caries and fillings. a case-control study Br Dent J. 187(5):1999;261-264.
7. Bangsi D., Ghadirian P., Ducic S., Morisset R., Ciccocioppo S., McMullen E., Krewski D. Dental amalgam and multiple sclerosis. a case-control study in Montreal, Canada Int J Epidemiol. 27(4):1998;667-671.
8. Fung Y.K., Meade A.G., Pack E.P., Blotcky A.J. Brain mercury in neurodegenerative disorders. J Toxicol-Clin Toxicol. 35(1):1997;49-54.
9. McLaurin J., Trudel G.C., Shaw I.T., Antel J.P., Cashman N.R. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol. 26(2):1995;283-293.
10. Craighead M., Tiwari P., Keynes R.G., Waters C.M. The human oligodendroglail cell line, MO3.13 can be protected from apoptosis using the general caspase inhibitor zVAD-FMK. J Neurosci Res. 57:1999;236-243.
11. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple Sclerosis. N Eng J Rodriguez Med. 343(13):2000;938-952.
12. Ozawa K., Schane K.G., Breitschop F.H., Bruck W., Budka H., Jellinger K., Lassman H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 117:1994;1311-1322.
13. Windebank A.J., McCall J.T., Dyck P.J. Metal neuropathy. Dyck P.J., Thomas P.K., Lanbert E.H., Runge R. In peripheral neuropathy. vol. II:1984;2133-2161 Saunders WB, Publisher, Philadelphia.
14. Akassoglou K., Bauer J., Kassiotis G., Pasparakis M., Lassmann H., Kollias G., Probert L. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signalling in the central nervous system of transgenic mice. Am J Pathol. 153:1998;801-813.
15. Navikas V., Link H. Review. cytokines and pathogenesis of multiple sclerosis J Neurosc Res. 45:1996;322-333.
16. Dowling P., Husar W., Menonna J., Donnenfeld H., Cook S., Sidhu M. Cell death and birth in multiple sclerosis brain. J Neurol Sci. 149:1997;1-11.
17. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Roy S., Vaillancourt J.P., Chapman K.T., Nicholson D.W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 272(29):1997;17907-17911.
18. Haviv R., Lindenboim L., Li H., Yuan J., Stein R. Need for caspases in apoptosis of trophic factor-deprived PC12 cells. J Neurosc Res. 50:1997;69-80.
19. Rao L., Perez D., White E. Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol. 135:1996;1441-1455.
20. Janicke R.U., Ng P., Sprengart M.L., Porter A.G. Caspase-3 is required for α-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem. 273:1998;15540-15545.
21. Feldman R.G. Neurological manifestations of mercury intoxication. Acta Neurol Scand. 92:1982;201-209.
22. Uzzel B., Olar J. Chronic low level mercury exposure and neuropsychological functioning. J Clin Exp Neuropsychol. 8:1986;581-593.
23. Halbach S. Estimation of mercury dose by a novel quantitation of elemental and inorganic species released from amalgam. Int Arch Occup Environ Health. 67(5):1995;295-300.
24. Jokstad A., Thomassen Y., Bye E., Clench-Aas J., Aaseth J. Dental amalgam and mercury. Pharmacol Toxicol. 70(4):1992;308-313.
25. Lorscheider F.L., Vimy M.J. Daily dose estimates of mercury from dental amalgams. J Dent Res. 70(3):1991;233-237.
26. Wolff M., Osborne J.W., Hanson A.L. Mercury toxicity and dental amalgam. Neurotoxicology. 4(3):1983;201-204.
27. Kingman A., Albertini T., Brown L.J. Mercury concentrations in urine and whole blood associated with amalgam exposure in a US military population. J Dent Res. 77(3):1998;461-471.
28. Ganss C., Gottwald B., Traenckner I., Kupfer J., Monch J., Gieler U., Klimek J. Relation between mercury concentrations in saliva, blood, and urine in subjects with amalgam restorations. Clin Oral Invest. 4(4):2000;206-211.
29. Jacobs M.B., Ladd A.C., Goldwater L.J. Absorption and excretion of mercury in man. VI. Significance of mercury in urine. Arch Environ Health. 9:1964;454-463.
30. Goldwater L.J., Ladd A.C., Jacobs M.B. Absorption and excretion of mercury in man. VII. Significance of mercury in blood. Arch Environ Health. 9:1964;735-741.
31. Echeverria D., Aposhian H.V., Woods J.S., Heyer N.J., Aposhian M.M., Bittner A.C., Mahurin J.R., Cianciola R.K. Neurobehavioral effects from exposure to dental amalgam Hg° new distinctions between recent exposure and Hg body burden FASEB J. 12:1998;971-980.
32. Pamphlett R., Waley P. Uptake of inorganic mercury by the human brain. Acta Neuropathol. 92(5):1996;525-527.
33. Newland M.C., Reile P.A. Blood and brain mercury levels after chronic gestational exposure to methylmercury in rats. Toxicol Sci. 50(1):1999;106-116.
34. Warfvinge K. Mercury distribution in the mouse brain after mercury vapour exposure. Int J Exp Pathol. 76(1):1995;29.
35. Huggins H.A., Levy T.E. Cerebrospinal fluid protein changes in multiple sclerosis after dental amalgam removal. Alternative Med Rev. 3(4):1998;295-300.
36. Siblerud R.L. A comparison of mental health of multiple sclerosis patients with silver/mercury dental fillings and those with fillings removed. Psychol Rep. 70(3 Pt 2):1992;1139-1151.
37. Siblerud R.L., Kienholz E. Evidence that mercury from silver dental fillings may be an etiological factor in multiple sclerosis. Sci Total Environ. 142(3):1994;191-205.